Crispr Therapeutics price target lowered to $82 from $89 at Citi

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the shares. While Casgevy is making progress based on 2024 revenue reported by Vertex (VRTX), it appears five patients have been treated since launch, the analyst tells investors in a research note. As such, Citi directs investors to Crispr’s accelerating pipeline and notes 2025 serves as a “catalyst-rich year.”